Biological Evaluation of Medical Devices

ISO 10993-1 is the internationally recognized standard for the biological evaluation of medical devices. Its full title is often given as ‘Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process’. In plain terms, it is the framework that tells you how to judge whether a device that touches the body is biologically safe for the way it is actually used.

It is important to be clear from the start about what ISO 10993-1 is and is not. It is Part 1 of a large series — the other parts cover specific evaluations such as cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation and chemical characterization. Part 1 is the master plan: it sets out how to think about biocompatibility, and then points you to the right parts of the series for the testing or data you need. Just as important, ISO 10993-1 is not a standard you get certified against. There is no certificate to hang on the wall. Instead, your biological evaluation is documented in a Biological Evaluation Plan and Report that becomes part of your technical file or regulatory submission.

The other defining feature is that ISO 10993-1 sits inside a risk-management process, aligned with the thinking in ISO 14971. It does not simply hand you a checklist of tests. It asks you to identify the biological risks that matter for your particular device, use existing knowledge where you can, and test only where a real gap remains.

ISO 10993-1 is relevant to any organization responsible for the safety of a medical device that contacts the human body, directly or indirectly. That contact is what triggers the need for a biological evaluation. Typical candidates include:

• Medical device manufacturers whose products touch skin, tissue, bone, blood or mucosal surfaces
• Implantable device makers — orthopedic, cardiovascular, dental and similar long-term contact devices
• Developers of surface-contact and external-communicating devices, from wound dressings to catheters and tubing
• Contract designers and manufacturers building devices for other brands
• Materials and component suppliers whose customers need biocompatibility evidence
• Regulatory and quality teams assembling a technical file for the EU MDR, an FDA submission, or another market

The need is almost always regulatory driven. A biological evaluation built on ISO 10993-1 is what regulators such as the FDA and Notified Bodies under the EU MDR expect to see as part of your submission or technical documentation. So while you are not pursuing a certificate, demonstrating biocompatibility through ISO 10993-1 is effectively required to place many devices on the market. One helpful point on scope: the standard classifies devices by the nature and duration of body contact, and that classification drives which biological effects you need to address. Getting that categorization right at the start is where a good evaluation begins.

ISO 10993-1 asks you to plan, justify and document a biological evaluation that is proportionate to your device — not to run every test in the series by default. The main themes are:

• Categorize the device by the nature of body contact (surface, external-communicating or implant) and the duration of contact (limited, prolonged or long-term).
• Build a Biological Evaluation Plan that identifies the biological endpoints relevant to that category — such as cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation effects and, where blood contact applies, hemocompatibility.
• Gather and use existing information first — material data, chemical characterization, literature and prior clinical history — so you test only where a genuine data gap remains.
• Consider chemical characterization of materials and extractables, which increasingly drives the evaluation and can reduce unnecessary biological testing.
• Apply risk management throughout, so every decision to test or not to test is justified against the risks of your specific device and use.
• Account for the finished device as it is actually made, including processing, sterilization and any residues, rather than the raw material alone.
• Document a Biological Evaluation Report that draws a clear line from device category, through the data and testing, to a reasoned conclusion on biological safety.

A recurring principle in the standard is to minimize unnecessary animal testing by making full use of existing data and chemical information. The evaluation is confirmed not by a certification audit but through regulatory review, where an assessor examines your plan, data and reasoning as part of your submission.

A quick clarification on wording, because it matters here: with ISO 10993-1 you are not chasing a certificate. What you are producing is a defensible biological evaluation that supports your regulatory submission or technical file. But the reason to do it well is every bit as compelling as any certification.

The first reason is market access. Without a sound biological evaluation, many devices simply cannot be cleared, approved or CE marked. Regulators expect ISO 10993-1 to be the backbone of your biocompatibility reasoning, so a weak or incomplete evaluation is one of the surest ways to attract questions, delays or an outright refusal.

The second reason is efficiency and cost. A risk-based evaluation done properly can save you from running expensive, time-consuming tests you never needed — and from the far costlier scenario of a submission rejected late because the biocompatibility rationale did not hold together. Using existing data and chemical characterization intelligently is often the difference between a lean program and a bloated one.

The deepest reason is patient safety and reputation. A device that provokes an unexpected biological reaction can harm patients and trigger field actions that dwarf the cost of the evaluation. A rigorous ISO 10993-1 process is one of the most reliable ways to protect the people who use your device — and the trust your name depends on.

We have spent more than 30 years helping companies build quality and regulatory systems, and we have guided 900+ organizations to successful outcomes with a 100% first-time pass rate on the audits and assessments we prepare them for. With ISO 10993-1 the target is a little different — there is no certificate, so what we build toward is a biological evaluation that stands up to regulatory review and slots cleanly into your submission or technical file.

Our proven 10-Step Approach adapts naturally to this work. We start by categorizing your device correctly by nature and duration of contact, then build a Biological Evaluation Plan that identifies the endpoints that genuinely matter. We help you assemble and use existing material data, chemical characterization and literature first, so testing is targeted rather than reflexive, and we keep the whole evaluation anchored in a risk-management process. Because we do the work alongside your team, the reasoning belongs to your people and holds up when an assessor pushes on it.

A hallmark of our work is documentation you will actually use — single-level documents, typically under 200 pages for the systems around your evaluation — rather than the sprawling files that confuse reviewers. We keep the Biological Evaluation Report clear and traceable, tie it into your ISO 13485 quality system and ISO 14971 risk file where relevant, and stand with you through regulatory questions. For most programs the readiness work runs about 3 to 9 months, depending on your device, the data you already hold, and how much testing turns out to be necessary.

• Miscategorizing the device. Getting the nature or duration of body contact wrong at the start sends the whole evaluation down the wrong path.
• Testing by default. Running the full battery of biological tests when existing data and chemical characterization could have answered the question — wasting time, money and, often, animals.
• Ignoring the finished device. Evaluating raw materials rather than the device as actually made, sterilized and processed, so residues and processing effects are missed.
• Treating 10993-1 as a test list. Skipping the risk-management reasoning that the standard is built around, and ending up with data but no defensible conclusion.
• Weak chemical characterization. Underinvesting in extractables and materials data that increasingly drives modern biocompatibility decisions.
• A disconnected evaluation. A biological file that does not link to the ISO 14971 risk management or the ISO 13485 quality system it should live inside.
• Thin documentation. A Biological Evaluation Report that states conclusions without showing the reasoning, which reviewers will not accept.
• Leaving it late. Starting the evaluation near submission, when the results can force redesign or delay the whole program.